$2 and $1 targets... Yucky wouldn't touch it with yours, page-433

Alf, my avg. buy price is virtually the same as yours at $2.51. It's frustrating because I have been watching RAC since 0.30 but never had the capital until the SP was ~$3.50. I've bought a few parcels on the way down to ameloriate some of the pain.

My question to you is (and this is something I ask myself almost daily), do you think the RAC team can execute the plan of developing bisantrene and its clinical package to a point where M&A occurs? If yes, what value to you think would be reasonable for such M&A activity. I personally think the answer to both of those questions is a) yes, and b) north of $1bn USD.

Now there is considerable risk in between now and then, which is reflected in the SP, perhaps its reflected too heavily but that's neither here nor there.

It at any point, the answer to the first question becomes No, then I'm out, and I'd suggest everyone do the same.

But in the meantime, if my thesis is correct, than neither my buy price or the current share price actually matter. Paper losses (and gains) don't mean anything other than psychologically. I'd suggest not worrying about the SP, what management are doing about it or any thing else of that nature.

If you think they can execute on the plan, you've got nothing to worry about.